Me. Weinblatt et al., Sulfasalazine treatment for rheumatoid arthritis: A metaanalysis of 15 randomized trials, J RHEUMATOL, 26(10), 1999, pp. 2123-2130
Objective. To assess the efficacy and safety of sulfasalazine (SSZ) compare
d to placebo and other disease modifying drugs.
Methods. A metaanalysis was performed on 15 randomized clinical trials of r
heumatoid arthritis (RA) that included SSZ (3 g/day average dose, 36 weeks
average followup) as a treatment. Eight trials included a placebo group (PL
), 2 hydroxychloroquine (HCQ) (350 mg/day average dose), 3 D-penicillamine
(D-Pen) (667 mg/day average dose), and 3 gold sodium thiomalate or aurothio
glucose (GST) (25 mg, 1 g/wk).
Results. Compared to PL, SSZ was superior for improvement in erythrocyte se
dimentation rate (ESR) (SSZ 37%, PL 14%; p < 0.0001), morning stiffness dur
ation (SSZ 61%, PL 33%; p = 0.008), pain visual analog scale (SZ 42%, PL 15
%; p < 0.0001), articular index (SSZ 46%, PL 20%; p < 0.0001), number of sw
ollen joints (SSZ 51%, PL 26%; p < 0.0001). number of painful joints (SSZ 5
9%, PL 33%; p = 0.004), and patient global assessment (SSZ 26%, PL 14%; ; p
= 0.02). Withdrawals from study because of adverse drug reactions were inc
reased (SSZ 24%, PL 7%; p < 0.0001). but lack of efficacy dropouts were dec
reased (SSZ 8%, PL 21%; p < 0.0001). Compared to HCQ, SSZ tended to have fe
wer lack of efficacy dropouts (SSZ 5%, HCQ 15%; p = 0.055) and improved ESR
(SSZ 43%, HCQ 26%; p = 0.10) and morning stiffness duration (SSZ 59%, HCQ
40%; p = 0.09). Compared to GST, adverse drug reaction dropouts were signif
icantly fewer (SSZ 12%, GST 29%; p < 0.0001), while withdrawals due to lack
of efficacy were greater (SSZ 13%, GST 4%; p = 0.006). More patients tende
d to complete treatment taking SSZ (SSZ 69%, GST 61%; p = 0.09).
Conclusion. Over all, the metaanalysis provides data that support the effec
tiveness of SSZ as a treatment for RA.